CD274 and neoplasm: High PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] is associated with greater benefit from pembrolizumab monotherapy, while patients with lower expression (TPS 1–49%) may benefit more often treated with combination regimens.